Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them

• US 8,648,191 B2
• Filed: 07/23/2009
• Issued: 02/11/2014
• Est. Priority Date: 08/08/2008
• Status: Active Grant

• Current Assignee: Boehringer Ingelheim International GmbH (C.H. Boehringer Sohn AG & Co. KG)
• Original Assignee: Boehringer Ingelheim International GmbH (C.H. Boehringer Sohn AG & Co. KG)
• Inventors: Himmelsbach, Frank, Jung, Birgit, Lotz, Ralf
• Primary Examiner(s): Wilson, James O
• Assistant Examiner(s): MASHA, OLUWAFEMI L
• Application Number:
  US13/057,872
• Publication Number:
  US 20110190248A1
• Time in Patent Office: 1,664 Days
• Field of Search: None
• US Class Current: 544/253
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/02 Nasal agents, e.g. decongestants
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 11/08 Bronchodilators
• CPC Class Codes: A61P 11/10 Expectorants
• CPC Class Codes: A61P 11/14 Antitussive agents
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: C07D 403/12 linked by a chain containing hetero atoms as chain links

Abstract

The present invention relates to cyclohexyloxy-substituted heterocycles of general formula (I)

the tautomers, the stereoisomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids, which have valuable pharmacological properties, particularly an inhibitory effect on signal transduction mediated by tyrosine kinases, the use thereof for the treatment of diseases, particularly tumoral diseases as well as benign prostatic hyperplasia (BPH), diseases of the lungs and airways and the preparation thereof.

Claims

1. A compound of formula (I)

2. The compounds according to claim 1,

wherein:

R^a denotes a group selected from among 3-chloro-2-fluoro-phenyl, 3-chloro-4-fluoro-phenyl, 5-chloro-2-fluoro-phenyl, 2-fluoro-3-methyl-phenyl, 2-fluoro-5-methyl-phenyl, 4-fluoro-3-methyl-phenyl and 3-chloro-2-methyl-phenyl group,

R^b and R^c which may be identical or different,

denote hydrogen or C_1-3-alkyl,

R^d denotes C_1-3-alkyl-O,

unless stated otherwise, the above-mentioned alkyl groups may be straight-chain or branched,

A denotes —

CH₂CH₂, wherein the —

CH₂CH₂—

group may be substituted by 1 or 2 methyl groups,

optionally in the form of the tautomers, the racemates, the enantiomers, the diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts thereof.

3. A pharmaceutical formulation containing a compound of formula (I) according to claim 1.

4. An orally administered pharmaceutical formulation according to claim 3.